MoonLake Immunotherapeutics MLTX
Set alert
11.47 USD -0.31 -2.63%
At close
11.41 -0.06 -0.52%
Pre-market · Nov 3, 7:54 AM ET
11.17 Day range 12.00
9.46 52-week range 23.29
- YTD
- -12.97%
- 1 year
- +13.56%
- Open
- 11.80
- Prev close
- 11.78
- Mkt cap
- 976.17M
- Vol
- 972.02K
- Avg vol
- 1.69M
- EPS
- -3.83
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 11.17
- High
- 12.00
- Forward P/E
- -3.54
- Beta
- 1.08
- Short ratio
- 4.01
- Inst. own
- 87.73%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 12.60
- 200-d avg
- 16.49
- 1y target
- 28.54
Analyst view
Consensus: buy
Buy
Price target (mean) 28.54 +148.8% upside
Now 11.47
- Target (low)
- 6.00
- Target (mean)
- 28.54
- Target (high)
- 50.00
Ratings (0m) 15 11 buy · 2 hold · 2 sell
- Strong buy1
- Buy10
- Hold2
- Sell2
- Strong sell0
Recommendation trend
- This month 15
- 1 month ago 15
- 2 months ago 15
- 3 months ago 15
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.78081 | -0.88 – -0.66 | -1.10 | +29.0% | 0 | 0.0% | 7 |
| Next quarter | -0.81387 | -1.01 – -0.67 | -0.92 | +11.5% | 0 | 0.0% | 7 |
| Current year | -3.38 | -3.67 – -2.91 | -3.53 | +4.3% | 0 | 0.0% | 7 |
| Next year | -3.33 | -4.15 – -2.59 | -3.38 | +1.6% | 19.04M | 0.0% | 9 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 13, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 20, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 1, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Jun 9, 2026 | BTIG | Reiterated | Buy | Buy |
| Jun 8, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 12, 2026 | Needham | Maintained | Buy | Buy |
| May 11, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 30, 2026 | BTIG | Reiterated | Buy | Buy |
| Mar 23, 2026 | Wolfe Research | Upgrade | Underperform | Outperform |
| Mar 19, 2026 | Rothschild & Co | Upgrade | Neutral | Buy |
| Mar 11, 2026 | Clear Street | Maintained | Buy | Buy |
| Mar 2, 2026 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Mar 2, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 26, 2026 | Needham | Reiterated | Buy | Buy |
| Feb 24, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Feb 23, 2026 | BTIG | Maintained | Buy | Buy |
| Feb 23, 2026 | Needham | Maintained | Buy | Buy |
| Feb 20, 2026 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Feb 9, 2026 | BTIG | Reiterated | Buy | Buy |
| Feb 3, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 15, 2026 | Goldman Sachs | Downgrade | Neutral | Sell |
| Jan 9, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 9, 2026 | BTIG | Upgrade | Neutral | Buy |
| Nov 21, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 3, 2025 | HC Wainwright & Co. | Upgrade | Neutral | Buy |
| Oct 29, 2025 | Citigroup | Downgrade | Neutral | Sell |
| Oct 2, 2025 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Sep 30, 2025 | Guggenheim | Maintained | Buy | Buy |
| Sep 30, 2025 | Wedbush | Maintained | Outperform | Outperform |